These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1011 related items for PubMed ID: 19937839

  • 21. Ionization-specific QSAR models of blood-brain penetration of drugs.
    Lanevskij K, Japertas P, Didziapetris R, Petrauskas A.
    Chem Biodivers; 2009 Nov; 6(11):2050-4. PubMed ID: 19937840
    [Abstract] [Full Text] [Related]

  • 22. Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.
    Cole S, Bagal S, El-Kattan A, Fenner K, Hay T, Kempshall S, Lunn G, Varma M, Stupple P, Speed W.
    Xenobiotica; 2012 Jan; 42(1):11-27. PubMed ID: 21970687
    [Abstract] [Full Text] [Related]

  • 23. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY, Liu H, Summerfield SG, Luscombe CN, Sahi J.
    Mol Pharm; 2016 May 02; 13(5):1540-50. PubMed ID: 27015243
    [Abstract] [Full Text] [Related]

  • 24. Case study: adapting in vitro blood-brain barrier models for use in early-stage drug discovery.
    Vandenhaute E, Sevin E, Hallier-Vanuxeem D, Dehouck MP, Cecchelli R.
    Drug Discov Today; 2012 Apr 02; 17(7-8):285-90. PubMed ID: 22033197
    [Abstract] [Full Text] [Related]

  • 25. Drug delivery and in vitro models of the blood-brain barrier.
    Cucullo L, Aumayr B, Rapp E, Janigro D.
    Curr Opin Drug Discov Devel; 2005 Jan 02; 8(1):89-99. PubMed ID: 15679176
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW.
    J Pharmacol Exp Ther; 2002 Dec 02; 303(3):1029-37. PubMed ID: 12438524
    [Abstract] [Full Text] [Related]

  • 29. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA.
    Chem Res Toxicol; 2011 Sep 19; 24(9):1420-56. PubMed ID: 21790149
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
    Cai H, Stoner C, Reddy A, Freiwald S, Smith D, Winters R, Stankovic C, Surendran N.
    Int J Pharm; 2006 Feb 03; 308(1-2):133-9. PubMed ID: 16352407
    [Abstract] [Full Text] [Related]

  • 31. Drug delivery to the central nervous system: a review.
    Misra A, Ganesh S, Shahiwala A, Shah SP.
    J Pharm Pharm Sci; 2003 Feb 03; 6(2):252-73. PubMed ID: 12935438
    [Abstract] [Full Text] [Related]

  • 32. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA.
    Trends Pharmacol Sci; 2008 Apr 03; 29(4):186-91. PubMed ID: 18353445
    [Abstract] [Full Text] [Related]

  • 33. In vivo rat PK profiling in drug discovery: new challenges.
    Zonzini L, Bianchi F, Cesari N, Sartori M.
    Expert Opin Drug Discov; 2010 Nov 03; 5(11):1031-7. PubMed ID: 22827743
    [Abstract] [Full Text] [Related]

  • 34. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J, Green AR.
    J Pharmacol Exp Ther; 2009 Dec 03; 331(3):767-74. PubMed ID: 19779129
    [Abstract] [Full Text] [Related]

  • 35. Building predictive ADMET models for early decisions in drug discovery.
    Penzotti JE, Landrum GA, Putta S.
    Curr Opin Drug Discov Devel; 2004 Jan 03; 7(1):49-61. PubMed ID: 14982148
    [Abstract] [Full Text] [Related]

  • 36. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states.
    Deo AK, Theil FP, Nicolas JM.
    Mol Pharm; 2013 May 06; 10(5):1581-95. PubMed ID: 23256608
    [Abstract] [Full Text] [Related]

  • 37. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H.
    Chem Biodivers; 2009 Nov 06; 6(11):1760-6. PubMed ID: 19937820
    [Abstract] [Full Text] [Related]

  • 38. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction.
    Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P.
    J Pharmacol Exp Ther; 2007 Jul 06; 322(1):205-13. PubMed ID: 17405866
    [Abstract] [Full Text] [Related]

  • 39. Blood-brain barrier permeability considerations for CNS-targeted compound library design.
    Hitchcock SA.
    Curr Opin Chem Biol; 2008 Jun 06; 12(3):318-23. PubMed ID: 18435937
    [Abstract] [Full Text] [Related]

  • 40. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 06; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.